Articles tagged with Breast Cancer
Researchers found that triple-negative breast cancer cells are addicted to cystine and die rapidly when deprived of it, suggesting a potential new treatment. Cystine-blocking molecules may be effective in targeting this pathway, which is also used by other aggressive cancers.
Researchers at Scripps Research Institute have developed a new structure-based drug design strategy to target the estrogen receptor, reducing resistance and side effects in hormone-driven breast cancer treatments. The approach uses x-ray crystallography to visualize how drugs interact with the receptor, allowing for the creation of bio...
The updated guideline suggests that more breast cancer patients can benefit from accelerated partial breast irradiation (APBI), including younger patients and those with low-risk ductal carcinoma in situ (DCIS). The guideline provides direction for the use of intraoperative radiation therapy (IORT) for early-stage breast cancer patients.
New report predicts 7,100 cancer deaths annually by 2035 linked to alcohol, with oesophageal cancer seeing largest increase. The NHS will face a £2 billion treatment bill, while over 1.2 million hospital admissions are forecasted.
The 2016 AAAS Kavli Science Journalism Awards honored journalists for their consequential medical research stories, including a Swedish documentary that raised questions about a surgeon's research conduct. The awards also recognized investigative reporting on topics such as breast cancer and research ethics.
A new study has identified BRD4 protein as a crucial driver of breast cancer cell dissemination, offering a promising new target for therapy. The findings may provide hope for patients with triple-negative breast cancer, the most aggressive and difficult-to-treat subtype.
Researchers at Texas A&M University found that breast cancer cells may evade treatment by consuming stem cells from bone marrow, making them difficult to kill. This mechanism could explain cancer recurrence and lead to new treatments, such as delivering toxic agents directly to cancer cells using stem cells as a delivery vehicle.
A study published in the Journal of General Internal Medicine found that Asian Americans have a high prevalence of undiagnosed type 2 diabetes and are less likely to undergo recommended screening. Only 47.1% of Asian Americans received appropriate screening, compared to 60.2% of non-Hispanic blacks.
Researchers created a new cancer drug using gold nanoparticles to deliver paclitaxel directly to tumors, increasing effectiveness while reducing devastating side effects such as hair loss and nerve pain. Early lab tests showed the therapy to be nearly as effective as a high dose of paclitaxel alone.
A new study by researchers at the University of Victoria and Australia's National Drug Research Institute found a statistically significant dose-response relationship between alcohol intake and risk of prostate cancer. Current drinkers who consumed high volumes had an increased risk, even at low-volume drinking levels.
The project aims to improve diagnosis and tailor treatment by analyzing the genome and expressed genes of tumour cells from 250 breast cancer patients. This personalized approach will help doctors choose the best treatment for individual patients, potentially increasing survival rates and reducing side effects.
A study by TSRI researchers reveals that macrophages can create vessel-like structures for delivering oxygen and nutrients to growing tumors, promoting cancer progression. This finding could lead to novel cancer therapies targeting immune system cells.
A randomized clinical trial found that both treatment arms met the primary safety endpoint, with improvements reported in vaginal atrophy and sexual interest for all patients. The study also revealed that 37% of patients had elevated estradiol levels at baseline, which could be attributed to estrogen-containing supplements.
Higher vitamin D levels in blood are associated with better overall survival in breast cancer patients, according to a new study published in JAMA Oncology. The research found stronger associations between higher vitamin D levels and improved survival in premenopausal women.
Researchers identified genetic mutations that distinguish aggressive rhabdoid meningiomas from benign forms, suggesting a potential new approach for clinical decision-making. The study found patients with BAP1 mutations had poor clinical outcomes and shorter disease progression times.
Women with higher vitamin D levels after a breast cancer diagnosis had significantly better long-term outcomes, including lower mortality and recurrence rates. The study found stronger associations among premenopausal women for breast-cancer-specific survival.
Ludwig researchers discover a targeted drug that overcomes suppressive immune cells, leading to improved responses to immune checkpoint blockade therapy in tumors with high concentrations of these cells. The findings offer a potential precision medicine approach for personalized treatment regimens.
Researchers found that tailored dose-dense chemotherapy did not improve 5-year breast cancer recurrence-free survival, overall survival, or distant disease-free survival compared to standard chemotherapy. However, the tailored group experienced more nonhematologic toxic effects.
A new study of over 200,000 cancer survivors found that those diagnosed at younger ages have a higher risk of death from heart disease. Cancer survivors diagnosed between 15-19 years old had a 4.2 times higher risk compared to the general population.
Pancreatic cancer is expected to become the third leading cause of death from cancer in the EU by 2017. The number of deaths from pancreatic cancer will overtake breast cancer mortality rates in the EU, with 91,500 estimated deaths next year.
A new study found that around 17% of women diagnosed with breast cancer visit their doctor with a symptom other than a lump. Non-lump symptoms, such as nipple abnormalities and breast pain, were more likely to delay diagnosis compared to those with a breast lump alone.
Breast cancer cells may use mesenchymal stem cells in bone marrow to spread to bone tissue. A study using a 3D scaffold model found that tumor-derived factors can promote maturation of MSCs into bone cells, with mechanical compression stimulating further bone development.
Researchers at Eindhoven University of Technology have created a breast-friendly method for detecting cancer without radiation, generating 3D images with improved accuracy. The new technology uses echography and blood vessel structure analysis to identify cancerous tumors.
A new series published in The Lancet highlights the need for international efforts to end preventable deaths from breast and cervical cancer, particularly in low- and middle-income countries. Cost-effective interventions, such as routine HPV vaccination and cervical screening, can significantly reduce mortality rates if implemented.
Researchers found that high levels of Manganese Superoxide Dismutase (MnSOD) trigger aggressive breast cancer cell behavior. By targeting MnSOD, scientists hope to develop effective therapeutic strategies against triple-negative breast cancer.
Scientists at The Wistar Institute discovered how MEK inhibitor trametinib controls tumor progression by reducing immune suppression and allowing anti-tumor T cells to target tumors. This finding provides new insights into the effects of targeted therapies on antitumor immunity.
Researchers silenced SIRT2 to accelerate the degradation of Slug protein, reducing tumor growth and invasiveness in basal-like breast cancer cells. The study revealed a direct relationship between SIRT2, Slug stability, and malignant behavior, providing new insights into treating aggressive basal-like breast cancers.
A new study suggests that a widely available web-based program can help cancer survivors reporting cognitive symptoms. The 15-week program improved self-reported cognitive function, lowered anxiety and depression, and improved fatigue. Objective neuropsychological function test results were not different between the two groups.
A study found that an online neurocognitive learning program reduced cognitive symptoms in cancer patients following chemotherapy. Participants who used the program showed improved cognitive function, reduced anxiety and depression, and better quality of life compared to those receiving standard care.
Researchers link PIP to cell-mediated immunity, suggesting its potential as a new target for immunotherapeutic agents. PIP may help the immune system recognize and destroy foreign cells, including tumor cells, offering a protective effect against breast cancer.
Researchers developed a three-dimensional mammary gland model that mimics healthy breast tissue structure and function. The model enables the study of disease mechanisms and drug screening, providing a significant breakthrough in understanding breast cancer.
Researchers investigate how queuine, produced by gut bacteria, affects breast cancer risk and growth. High levels of queuine-modified tRNAs may speed up protein production in rapidly dividing cancer cells.
Researchers at University of Granada found telerehabilitation through Skype reduces pain, fatigue, and improves strength in women with breast cancer. An 8-week exercise program led to significant benefits that lasted 6 months after completion.
The study, involving 1,531 women, found that breast reconstruction following mastectomy for breast cancer yields similar benefits for all age groups, with no significant increase in complication risk. The procedure is generally successful and should not be disqualifying based on age alone.
The ECOG-ACRIN Cancer Research Group is recruiting medical facilities for the Tomosynthesis Mammography Imaging Screening Trial (TMIST), a large-scale breast cancer screening trial comparing digital breast tomosynthesis with standard digital mammography. The study aims to provide a modern basis for continued use of mammography.
A study found that tumor genome testing helped physicians identify patients who could benefit from chemotherapy, while those for whom it could be safely omitted received personalized recommendations. The test eliminated racial/ethnic disparities in testing or treatment, but many women inaccurately recalled their results.
A new cancer treatment combines four therapies to activate both branches of the immune system, leading to complete disappearance of large tumors in mice. The approach allows the immune system to remember the target and destroy new cancer cells that appear after treatment.
A study at McGill University Health Centre found that women with tumors expressing the prolactin receptor had a less aggressive breast cancer and better prognosis. The research suggests screening for the prolactin receptor could indicate which patients might benefit from new treatments, potentially revolutionizing breast cancer therapies.
A new study found that a genetic test assessing breast cancer recurrence risk is being used to guide chemotherapy decisions in early-stage breast cancer patients. The test, which looks at 21 genes known to increase the risk of cancer recurrence, has been shown to align treatment recommendations with individual patient profiles.
Researchers found a specific rearrangement of collagen fibers surrounding tumors associated with early death, which may indicate poorer survival rates. The study suggests that understanding collagen's role in cancer could lead to new therapeutic targets for pancreatic cancer.
A multidisciplinary team has developed a new method to automate the screening of breast cancer histopathology images, improving detection rates. The technique uses image-processing methods to identify cancerous cells, overcoming challenges posed by clustered and vague boundaries.
Researchers have identified a mechanism by which tumors recruit bone mesenchymal stem cells and convert them into cancer-associated fibroblasts, facilitating tumor progression. Basic fibroblast growth factor (bFGF) signaling plays a crucial role in this process, suggesting new therapeutic targets for suppressing tumor growth.
African American women are diagnosed with breast cancer at younger ages and face higher mortality rates due to more aggressive ER-negative tumors. Researchers identified modifiable risk factors, including breastfeeding and waist-to-hip ratio, that may help reduce personal risk of ER-negative breast cancer.
A study found that nearly 30% of women with breast cancer are not getting the recommended annual mammogram and surveillance imaging. Factors such as younger age, black race, and lack of insurance are associated with underutilization of breast imaging.
Eleven cancers causing most loss of healthy life years in the US are closely associated with preventable risk factors like smoking and alcohol. Lung cancer accounts for 24% of the burden, followed by breast, colorectal, pancreatic, prostate, leukemia, liver, brain, non-Hodgkin lymphoma, and ovarian cancers.
Contralateral prophylactic mastectomy (CPM) is being performed at a rate more than double what it was 10 years ago, with fear of recurrence as the leading reason. Studies found that patients are misinformed about CPM being the best treatment for breast cancer, which may be driving its increased popularity.
Researchers develop artificial cell-like spheres from natural proteins to study drug transport and variability. Variants in genes ABCB1 and CYP19A1 associated with anastrozole concentrations and joint pain in breast cancer patients.
New research from The Wistar Institute found that estrogen signaling is responsible for immunosuppressive effects in the tumor microenvironment across various cancers. This discovery paves the way for combining anti-estrogen therapy with immunotherapeutic treatments to extend survival in patients.
University of Oklahoma researchers have designed a novel photothermal therapy that eliminates tumors without affecting healthy cells. The therapy uses single-walled carbon nanotubes to target specific cancer cells in breast, bladder, esophageal, and melanoma cancers.
PharmaMar's Phase 2 study shows significant reduction in tumor size and improved survival rates for patients with BRCA 1/2 metastatic breast cancer. The trial achieved an overall response rate of 41% with a 61% response rate in the BRCA 2 subgroup.
A Phase III trial found ribociclib improved PFS of post-menopausal women with hormone receptor-positive metastatic breast cancer by 44 percent compared to hormone therapy alone. The study also showed a higher ORR in patients receiving ribociclib, with serious adverse events occurring less than five percent overall.
A study published in the British Journal of Cancer predicts that more than 352,000 people will be diagnosed with cancer each year in the UK by 2035, a rise of 150,000 cases annually. The projected increase is largely attributed to an ageing and growing population, as well as lifestyle factors such as obesity and smoking.
A report by Brain Tumour Research reveals that brain tumours are the biggest killer of children and young adults, with only £4 million spent on research per death. The charity is campaigning for increased funding to advance treatments and find a cure.
A new study suggests that combining an experimental PARP inhibitor with an epigenetic drug can strengthen treatment effectiveness against breast cancer cells without BRCA mutations, as well as leukemia cells. The combination therapy resulted in a strong antitumor response and halted tumor growth.
A new study from MD Anderson found substantial variation in the costs of breast cancer treatment for different chemotherapy regimens, with varying prices by up to $20,354. The researchers suggest that informed choice of chemotherapy could impact costs nationally by $1 billion annually.
A new study finds that breast cancer chemotherapy regimens with similar efficacy have significantly varying costs, affecting patients' financial burden. The study highlights the need for accessible information to inform treatment decisions and promote well-informed shared decisions regarding treatment options.
Researchers found that fulvestrant significantly increases progression-free survival in hormone-receptor-positive advanced breast cancer patients, especially those with lower-volume disease. The treatment also showed similar health-related quality of life compared to anastrozole and was well-tolerated.
The MONALEESA2 study shows a significant improvement in progression-free survival for postmenopausal women with hormone receptor-positive advanced breast cancer when treated with ribociclib plus letrozole. The combination also resulted in higher objective response rates and improved clinical benefits.
A study by University of Minnesota researchers found that elevated levels of APOBEC3B in breast cancer cells lead to reduced response to tamoxifen therapy. Depletion of the protein accelerates development of resistance, while increased production speeds it up.
Despite previous concerns, a new review of evidence suggests that night shift work is unlikely to increase breast cancer incidence. A meta-analysis of three large UK studies and seven previously published studies found no significant association between night shift work and breast cancer risk.